Lacey J. Padrón, PhD, vice president, Informatics, Parker Cancer Institute for Immunotherapy, discusses biosignatures found in a phase 2 study (NCT03214250) in pancreatic cancer.

In this open-label, multicenter trial, oncologists examined the efficacy of gemcitabine and nab-paclitaxel plus sotigalimab (Apexigen; formerly APX 005M) and/or nivolumab (Opdivo) in patients with metastatic pancreatic adenocarcinoma.

The study revealed biomarkers of response, particularly to the sotigalimab/chemotherapy and nivolumab/chemotherapy combinations, Padrón explains. Moreover, in the patients’ blood and tumor at baseline, investigators found signals that correlated with longer survival, Padrón adds.

Those biosignature were distinct for the 2 combinations, and they related closely to the mechanisms of action of sotigalimab and nivolumab, respectively, Padrón concludes.

Videos

Lacey J. Padrón, PhD, discusses biosignatures found in a phase 2 study in pancreatic cancer. 


Lacey J. Padrón, PhD

Articles

Dr. Padrón on Biosignatures Found from a Phase 2 Study in Pancreatic Cancer